AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26447461 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wound infiltration (CWI)
Number of subjects: 50
Study 26447461 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 50
Study 26447461 — intervention group
Group type: EXPERIMENTAL
Intervention: CWI
Number of subjects: 50
Study 26447461 — intervention group
Group type: COMPARATOR
Intervention: TEA
Number of subjects: 50
Study 24351063 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical activity intervention
Number of subjects: 316
Study 24351063 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders and shorter participant information leaflet
Number of subjects: 316
Study 21316442 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RE)
Number of subjects: 71
Study 21316442 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE)
Number of subjects: 71
Study 21316442 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 71
Study 20037103 — intervention group
Group type: EXPERIMENTAL
Intervention: Single aortic clamp (SC group)
Number of subjects: 22
Study 20037103 — intervention group
Group type: COMPARATOR
Intervention: Conventional multiple aortic side‐clamp technique (MC group)
Number of subjects: 22
Study 17536871 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin (300mg/4mL) administered twice daily via nebulizer for 4 weeks
Number of subjects: 59
Study 17536871 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily via nebulizer for 4 weeks
Number of subjects: 59
Study 14973517 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg/nitrendipine 20 mg (E/N)
Number of subjects: 97
Study 14973517 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L/H)
Number of subjects: 97
Study 11677518 — intervention group
Group type: EXPERIMENTAL
Intervention: SUPPORT intervention (delivered by 17 nurses)
Number of subjects: 10000
Study 9599104 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban
Number of subjects: 3232
Study 8273796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (0.5g tid) and tobramycin (4 mg/kg tid)
Number of subjects: 39
Study 8273796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2596737 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 1,500,000 IU streptokinase
Number of subjects: 40
Study 2596737 — intervention group
Group type: COMPARATOR
Intervention: Routine anticoagulant therapy (Control)
Number of subjects: 40
Study 1093634 — intervention group
Group type: EXPERIMENTAL
Intervention: Proflavine photoinactivation
Number of subjects: 36
Study 1093634 — intervention group
Group type: COMPARATOR
Intervention: 0.5 per cent. idoxuridine ointment (IDU)
Number of subjects: 36
Study 1093634 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 36
Study 30852657 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D-fortified foods (yoghurt, cheese, eggs, crisp bread) providing 20 µg vitamin D3/day
Number of subjects: 143
Study 30852657 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 143
Study 29090352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ORP values at 12 h post-CPB
Number of subjects: 162
Study 29090352 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower ORP values at 6 h post-CPB
Number of subjects: 162
Study 27773378 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist group (self-administered checklist and paper feedback)
Number of subjects: 20
Study 27773378 — intervention group
Group type: COMPARATOR
Intervention: Control group (paper feedback only)
Number of subjects: 20
Study 23638904 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index (LGI) diet, n=33
Number of subjects: 58
Study 23638904 — intervention group
Group type: COMPARATOR
Intervention: Conventional high-fibre diet (HF), n=25
Number of subjects: 58
Study 23207891 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week proprioception training program
Number of subjects: 44
Study 21066883 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulated acupuncture
Number of subjects: 50
Study 21066883 — intervention group
Group type: COMPARATOR
Intervention: Non-manipulated acupuncture
Number of subjects: 50
Study 21066883 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment group (manipulated acupuncture)
Number of subjects: 50
Study 21066883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 50
Study 18853583 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine with adrenaline and fentanyl (LAF)
Number of subjects: 90
Study 18853583 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 90
Study 18853583 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 90
Study 18853583 — intervention group
Group type: COMPARATOR
Intervention: LAF, 0.75% ropivacaine, 0.5% levobupivacaine
Number of subjects: 90
Study 16902063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber, low-fat diet with daily aerobic exercise for 3 weeks
Number of subjects: 22
Study 12926747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elders with high dental status
Number of subjects: 29
Study 12926747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elders with middle dental status
Number of subjects: 29
Study 12926747 — intervention group
Group type: EXPERIMENTAL
Intervention: Elders with low dental status
Number of subjects: 29
Study 12926747 — intervention group
Group type: COMPARATOR
Intervention: Young adults (control group)
Number of subjects: 29
Study 11778207 — intervention group
Group type: EXPERIMENTAL
Intervention: Early extubation followed by non-invasive mechanical ventilation (MV) via facial mask in 11 cases (study group)
Number of subjects: 22
Study 11778207 — intervention group
Group type: COMPARATOR
Intervention: Continuous invasive MV in 11 cases (control group)
Number of subjects: 22
Study 8733148 — intervention group
Group type: EXPERIMENTAL
Intervention: Affine transformation applied to one of two identical patterns in a 'same' trial.
Number of subjects: 0
Study 8733148 — intervention group
Group type: EXPERIMENTAL
Intervention: Affine transformation applied after the point lying on the diagonal bisector was perturbed in a 'different' trial.
Number of subjects: 0
Study 8733148 — intervention group
Group type: EXPERIMENTAL
Intervention: Probabilistic model of discrimination performance using qualitative cues.
Number of subjects: 0
Study 1895677 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ileal bypass (PIB) surgery
Number of subjects: 146
Study 1895677 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control)
Number of subjects: 146
Study 1895677 — intervention group
Group type: EXPERIMENTAL
Intervention: PIB stone-formers (S)
Number of subjects: 146
Study 1895677 — intervention group
Group type: EXPERIMENTAL
Intervention: PIB non-stone formers (N)
Number of subjects: 146
Study 6873549 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) at a single weekly dose of 15 mg/kg
Number of subjects: 13
Study 31356221 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based head-mounted display (HMD) for vestibular rehabilitation
Number of subjects: 30
Study 29532054 — intervention group
Group type: EXPERIMENTAL
Intervention: mPATH‐CRC (digital health intervention using an iPad application)
Number of subjects: 450
Study 29532054 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 450
Study 29532054 — intervention group
Group type: EXPERIMENTAL
Intervention: mPATH‐CRC
Number of subjects: 450
Study 28247026 — intervention group
Group type: COMPARATOR
Intervention: Normal night of sleep (CON, 7.56±0.63 h)
Number of subjects: 16
Study 28247026 — intervention group
Group type: EXPERIMENTAL
Intervention: Half of usual time in bed (DEP, 3.83±0.33 h)
Number of subjects: 16
Study 28247026 — intervention group
Group type: EXPERIMENTAL
Intervention: DEP condition
Number of subjects: 16
Study 28247026 — intervention group
Group type: COMPARATOR
Intervention: CON condition
Number of subjects: 16
Study 26297203 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing 52-mg IUD (LNG-IUD)
Number of subjects: 32
Study 26297203 — intervention group
Group type: COMPARATOR
Intervention: Copper T380A IUD (Cu-IUD)
Number of subjects: 32
Study 23972263 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR (20 mg intramuscular injections every 28 days for 3 years)
Number of subjects: 79
Study 23972263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution every 28 days for 3 years)
Number of subjects: 79
Study 23972263 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide-LAR
Number of subjects: 79
Study 23972263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 21038631 — intervention group
Group type: EXPERIMENTAL
Intervention: Bunnell suture with reinforcement by a graft of the fascia lata
Number of subjects: 43
Study 21038631 — intervention group
Group type: COMPARATOR
Intervention: Simple end-to-end Bunnell suture
Number of subjects: 43
Study 19120513 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil 50 mg daily
Number of subjects: 59
Study 19120513 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin 0.2 mg once daily
Number of subjects: 59
Study 16730924 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline transdermal system (STS)
Number of subjects: 300
Study 16730924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 14567252 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (CAM)
Number of subjects: 65
Study 14567252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir (CFDN)
Number of subjects: 65
Study 10963930 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually focused cognitive-behavioral treatment
Number of subjects: 149
Study 10963930 — intervention group
Group type: COMPARATOR
Intervention: Relationship-focused community reinforcement approach
Number of subjects: 149
Study 9011971 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffer solution
Number of subjects: 502
Study 9011971 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 502
Study 8214269 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% niclosamide lotion applied daily for five months
Number of subjects: 186
Study 8214269 — intervention group
Group type: COMPARATOR
Intervention: Placebo lotion applied daily for five months
Number of subjects: 186
Study 3323611 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BCKA content supplement
Number of subjects: 0
Study 3323611 — intervention group
Group type: COMPARATOR
Intervention: Lower BCKA content supplement
Number of subjects: 0
Study 30562772 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibet plateau group
Number of subjects: 70
Study 30562772 — intervention group
Group type: COMPARATOR
Intervention: Plain group
Number of subjects: 70
Study 26806956 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-remifentanil
Number of subjects: 50
Study 26806956 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-remifentanil
Number of subjects: 50
Study 24253234 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa/entacapone (LCE)
Number of subjects: 95
Study 24253234 — intervention group
Group type: COMPARATOR
Intervention: Levodopa/carbidopa (LC)
Number of subjects: 95
Study 24589538 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma-Lyte A
Number of subjects: 46
Study 24589538 — intervention group
Group type: COMPARATOR
Intervention: 0.9% sodium chloride injection
Number of subjects: 46
Study 24589538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis
Number of subjects: 46
Study 22910317 — intervention group
Group type: EXPERIMENTAL
Intervention: Vatalanib (PTK787/ZK222584)
Number of subjects: 141
Study 22910317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 20041430 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriaforce tincture
Number of subjects: 3
Study 20041430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo fresh plant extract tablets
Number of subjects: 3
Study 20041430 — intervention group
Group type: EXPERIMENTAL
Intervention: EGb 761 tablets
Number of subjects: 3
Study 18001672 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2a plus ribavirin
Number of subjects: 208
Study 18001672 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha-2b plus ribavirin
Number of subjects: 208
Study 16138418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetate dialysate
Number of subjects: 41
Study 16138418 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate dialysate
Number of subjects: 41
Study 11873071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (rIL-2) 4.5 MIU
Number of subjects: 511
Study 11873071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (rIL-2) 7.5 MIU
Number of subjects: 511
Study 11873071 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interleukin-2 (rIL-2)
Number of subjects: 511
Study 11873071 — intervention group
Group type: COMPARATOR
Intervention: No rIL-2 (Control)
Number of subjects: 511
Study 10190407 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pacing
Number of subjects: 81
Study 10190407 — intervention group
Group type: COMPARATOR
Intervention: Inactive pacing
Number of subjects: 81
Study 8871752 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Epoetin alfa regimen (600 IU/kg)
Number of subjects: 0
Study 8871752 — intervention group
Group type: COMPARATOR
Intervention: Daily Epoetin alfa regimen (300 IU/kg)
Number of subjects: 0
Study 1624722 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 98
Study 1624722 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 98
Study 1624722 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 6705479 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc aerosol particles
Number of subjects: 20
Study 6705479 — intervention group
Group type: EXPERIMENTAL
Intervention: 81mKr gas
Number of subjects: 20
Study 6705479 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol deposition abnormalities
Number of subjects: 20
Study 31537332 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 308
Study 31537332 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 308
Study 28806275 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Carbohydrate Loading (PLA + LOAD)
Number of subjects: 18
Study 28806275 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine + Moderate Carbohydrate (CR + MOD)
Number of subjects: 18
Study 28806275 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine + Carbohydrate Loading (CR + LOAD)
Number of subjects: 18
Study 28806275 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR)
Number of subjects: 18
Study 28806275 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycogen Depletion
Number of subjects: 18
Study 27841974 — intervention group
Group type: EXPERIMENTAL
Intervention: Three needle acupuncture (TNA)
Number of subjects: 58
Study 27841974 — intervention group
Group type: EXPERIMENTAL
Intervention: SNA plus manual stimulation (SNA+MS)
Number of subjects: 58
Study 27841974 — intervention group
Group type: COMPARATOR
Intervention: Single needle acupuncture (SNA)
Number of subjects: 58
Study 27841974 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 58
Study 25072098 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide (CO) measurement
Number of subjects: 1768
Study 25072098 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled carbon monoxide (CO) measurement after adjusting for smoking behavior
Number of subjects: 1768
Study 25072098 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes smoked per day
Number of subjects: 1768
Study 23152839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg weekly subcutaneous injections (n = 39)
Number of subjects: 58
Study 23152839 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 58
Study 23152839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen
Number of subjects: 58
Study 23152839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: PCMH principles (personal physician, physician‐directed team, whole‐person orientation, coordination of care, quality and safety, enhanced access)
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal physician principle, particularly continuity with the same physician
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of visits within 2 years
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐person orientation principle
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a well‐visit within 5 years
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for chronic diseases
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral systems to link patients to community programs for preventive counseling
Number of subjects: 24
Study 20212297 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of clinical decision‐support tools
Number of subjects: 24
Study 17352962 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon juice (780 g/day)
Number of subjects: 23
Study 17352962 — intervention group
Group type: EXPERIMENTAL
Intervention: Watermelon juice (1560 g/day)
Number of subjects: 23
Study 17352962 — intervention group
Group type: COMPARATOR
Intervention: Control (0 g watermelon juice)
Number of subjects: 23
Study 15730171 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol and 1 mg norethisterone acetate
Number of subjects: 47
Study 15730171 — intervention group
Group type: COMPARATOR
Intervention: 2 mg estradiol and 5 mg norethindrone
Number of subjects: 47
Study 11889394 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal sensitivity, intact laryngeal adductor reflex)
Number of subjects: 122
Study 11889394 — intervention group
Group type: EXPERIMENTAL
Intervention: Absent LAR group (severe sensory deficits)
Number of subjects: 122
Study 11889394 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal sensitivity)
Number of subjects: 122
Study 9539585 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided BronchoCath double-lumen tube (R-DLT)
Number of subjects: 40
Study 9539585 — intervention group
Group type: COMPARATOR
Intervention: Univent tube with bronchial blocker (R-UBB)
Number of subjects: 40
Study 7840381 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy with endoscopic linear stapler (LAS)
Number of subjects: 253
Study 7840381 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy with catgut ligatures (LAL)
Number of subjects: 253
Study 7840381 — intervention group
Group type: COMPARATOR
Intervention: Open Appendectomy (OA)
Number of subjects: 253
Study 1470875 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid expansion (once a day)
Number of subjects: 30
Study 1470875 — intervention group
Group type: COMPARATOR
Intervention: Slow expansion (once a week)
Number of subjects: 30
Study 6437474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 97
Study 6437474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 31044624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureteroscopy (URS)
Number of subjects: 125
Study 31044624 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy (PCNL)
Number of subjects: 125
Study 29569328 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group (n=19)
Number of subjects: 39
Study 29569328 — intervention group
Group type: COMPARATOR
Intervention: Non-contingent group (n=20)
Number of subjects: 39
Study 26337026 — intervention group
Group type: EXPERIMENTAL
Intervention: MDRNSTAT
Number of subjects: 0
Study 24909481 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (EA)
Number of subjects: 60
Study 24909481 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 60
Study 22015616 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus administration of abciximab
Number of subjects: 16
Study 22015616 — intervention group
Group type: COMPARATOR
Intervention: Intravenous bolus administration of abciximab
Number of subjects: 16
Study 20570084 — intervention group
Group type: EXPERIMENTAL
Intervention: United States (5.3% prevalence of alcohol abuse)
Number of subjects: 0
Study 20570084 — intervention group
Group type: COMPARATOR
Intervention: South Korea (2.0% prevalence of alcohol abuse)
Number of subjects: 0
Study 20570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Korea (5.1% prevalence of alcohol dependence)
Number of subjects: 0
Study 20570084 — intervention group
Group type: COMPARATOR
Intervention: United States (4.4% prevalence of alcohol dependence)
Number of subjects: 0
Study 20570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Men in both countries
Number of subjects: 0
Study 20570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Youngest age groups in both countries
Number of subjects: 0
Study 20570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Men, employed or never married individuals in both countries
Number of subjects: 0
Study 20570084 — intervention group
Group type: EXPERIMENTAL
Intervention: Age factor in the United States and Korea
Number of subjects: 0
Study 17524574 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive referral to self-help groups (SHGs)
Number of subjects: 345
Study 17524574 — intervention group
Group type: COMPARATOR
Intervention: Standard referral to self-help groups (SHGs)
Number of subjects: 345
Study 16360543 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1000 mg/m2, days 1, 8) plus Docetaxel (75 mg/m2, day 1)
Number of subjects: 305
Study 16360543 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1250 mg/m2, bid days 1-14) plus Docetaxel
Number of subjects: 305